Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm [PDF]
Haematologica, 2023 Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that presents with characteristic dark purple skin papules, plaques, and tumors, but may also involve the bone marrow, blood, lymph nodes, and central nervous system ...
Marlise R. Luskin, Andrew A. Lane
doaj +4 more sources
New leads to enhance tagraxofusp efficacy in pDC-AML [PDF]
Blood Neoplasiapeer ...
Morgane Boichut +11 more
doaj +5 more sources
Hematopoietic effects of tagraxofusp in treatment‐naive patients with blastic plasmacytoid dendritic cell neoplasm [PDF]
CancerAbstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic neoplasm that expresses CD123, is often observed in the bone marrow (BM), as well as skin, blood, and viscera. Tagraxofusp, a first‐in‐class CD123‐targeted therapy, is the only drug approved to treat BPDCN.
Kendra Sweet +2 more
exaly +3 more sources
Durable outcomes with manageable safety leading to prolonged survival with tagraxofusp for treatment-naïve patients with blastic plasmacytoid dendritic cell neoplasm: real world results from a European Named Patient Program [PDF]
Annals of HematologyBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive, poor-prognostic, and CD123-overexpressing orphan hematologic malignancy for which tagraxofusp, a CD123-targeted fusion protein, is the only approved drug. In this retrospective study,
Eric Deconinck +2 more
exaly +3 more sources
Use of alternative components to facilitate timely administration of tagraxofusp [PDF]
Journal of Oncology Pharmacy PracticeFong RL, Ayres C, Browne R.
exaly +4 more sources
Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas
Cells, 2023 In recent years, targeted (biological) therapies have become available also for primary cutaneous T-cell lymphomas (PCTCLs) including anti-CD30 (brentuximab vedotin) in mycosis fungoides, primary cutaneous anaplastic large T-cell lymphoma, lymphomatoid ...
Benedetta Sonego +5 more
doaj +2 more sources
Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction [PDF]
Haematologica, 2022 Deepak B. Vangala +5 more
doaj +4 more sources
Hyper-CVAD combined with Venetoclax for relapsed pediatric blastic plasmacytoid dendritic cell neoplasm (BPDCN): A case report and literature review. [PDF]
Leukemia Research Reports, 2022 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare type of leukemia in children, Although BPDCN is a chemo-sensitive tumor, the relapse rate is very high.
Dima Abla +4 more
doaj +2 more sources
Tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a profile of its use
Drugs & Therapy Perspectives, 2021 The CD123-directed cytotoxin tagraxofusp (ELZONRIS®) is the first treatment approved in the EU for first-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults. BPDCN is a rare disease that affects mainly older patients and is usually treated with acute leukaemia-type multi-drug chemotherapy regimens followed, if possible, by ...
Anthony Markham (4891627)
openaire +2 more sources
eJHaemBlastic plasmacytoid dendritic cell neoplasm (BPDCN) predominantly occurs in adults ≥60 years old; 10–20% of cases are pediatric or adolescent/young adult (AYA) patients.
Naveen Pemmaraju +11 more
doaj +2 more sources